Reporting of Safety Events during Anti-VEGF Treatment: Pharmacovigilance in a Noninterventional Trial

Figure 1

Incidence rates for adverse events by category across indications (nAMD, DME, and RVO). Nonserious AEs and ADRs occurred more frequently among RVO patients compared to nAMD and DME patients. Serious AEs and ADRs occurred slightly less frequently in nAMD patients than in RVO and DME. AE, adverse event; ADR, adverse drug reaction; DME, diabetic macular edema; nAMD, neovascular age-related macular degeneration; RVO, retinal vein occlusion.